IDEXX Laboratories (IDXX)
(Delayed Data from NSDQ)
$476.27 USD
+2.99 (0.63%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $476.27 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$476.27 USD
+2.99 (0.63%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $476.27 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth D Momentum D VGM
Zacks News
Bruker (BRKR) at a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
The new 52-week high of Bruker (BRKR) came on the back of several new initiatives, the most recent one being the introduction of the new CE-IVD marked Fungiplex Candida fast diagnostic assay.
OPKO Health (OPK) Signs New Agreement with Japan Tobacco
by Zacks Equity Research
OPKO Health's (OPK) new agreement with Japan Tobacco will enhance prospects of its kidney drug RAYALDEE in Japan.
LabCorp (LH) Strong on Strategic Planning, Competition Rife
by Zacks Equity Research
LabCorp (LH) grows on strong diagnostics business amid softness in the Covance drug development business.
DENTSPLY SIRONA Strong on Deal Renewals, Forex Woes Stay
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) renewed distribution deal will aid the company to gain market traction. However, forex woes remain a concern.
Ecolab (ECL) to Divest Equipment Care Segment, Shares Fall
by Zacks Equity Research
In August, management at Ecolab (ECL) announced that equipment care business has been witnessing a quiet period, registering just 2% growth on a year-over-year basis in the last quarter.
Veeva Systems (VEEV) Rides High on Commercial Cloud Platform
by Zacks Equity Research
The cost-effectiveness of cloud-based applications over in-premise applications is attracting life science companies. Veeva's (VEEV) industry-specific focus lends it a significant leverage.
Henry Schein Closes Merritt Buyout, Expands in Animal Health
by Zacks Equity Research
Henry Schein (HSIC) is consistently trying to expand its Animal Health business.
CryoLife to Buy JOTEC, Preliminary Revenue Result Out for Q3
by Zacks Equity Research
CryoLife (CRY) gained access to the $2-billion global market for stent grafts through JOTEC deal.
Mazor Projects Higher Q3 Revenues, Clinches Mazor X Orders
by Zacks Equity Research
Mazor's (MZOR) strong booking and order backlog from Mazor X system sales is likely to boost fortunes in the global spine surgery space.
QIAGEN Banks on Tie-Ups & Product Launches, Competition Rife
by Zacks Equity Research
The market is upbeat about QIAGEN's (QGEN) partnership and co-marketing agreement with CENTOGENE AG to boost its bioinformatics portfolio.
Express Scripts (ESRX) to Buy eviCore, Fortify PBM Business
by Zacks Equity Research
Express Scripts (ESRX) is consistently trying to expand its core PBM business.
The Zacks Analyst Blog Highlights: IDEXX Laboratories, Steris, K2M Group Holdings, Tandem Diabetes Care and Intersect ENT
by Zacks Equity Research
The Zacks Analyst Blog Highlights: IDEXX Laboratories, Steris, K2M Group Holdings, Tandem Diabetes Care and Intersect ENT
5 MedTech Stocks for Stellar Returns in Q3
by Zacks Equity Research
Here we take a sneak peek into two burning issues that are likely to impact the quarterly numbers in the MedTech fraternity.
4 Top Growth Picks as MedTech Battle Rages On
by Zacks Equity Research
Trump's Obamacare replacement saga has made growth picks great opportunities for investors in MedTech sector.
Pacific Biosciences, Bluebee Team Up for De Novo Sequencing
by Zacks Equity Research
With increasing demand for SMRT sequencing in the genomics community, both Pacific Biosciences (PACB) and partner Bluebee expect a huge customer adoption of integrated de novo assembly pipeline.
QIAGEN Partners With CENTOGENE, Boosts Bioinformatics Suite
by Zacks Equity Research
QIAGEN (QGEN) makes another encouraging move to expand its advanced bioinformatics portfolio and add additional capabilities, partners CENTOGENE.
Illumina (ILMN) Strong on Product Launches, Competition Rife
by Zacks Equity Research
Illumina rides high on product launches, including the latest release of VeriSeq NIPT in Europe, and strong uptake of NovaSeq. Weak margins remain a concern.
Fresenius Medical (FMS) Well Poised on Growth Strategy 2020
by Zacks Equity Research
Fresenius Medical (FMS) is banking on its Growth Strategy 2020 plan for gaining market traction in the future. However, lackluster performance in the bourse is a concern.
Boston Scientific Grows on New Products, Currency Woe Ails
by Zacks Equity Research
Boston Scientific (BSX) is gaining traction on product launch and accretive acquisitions. Yet an unfavorable currency movement is a major dampener.
DaVita Banks on Acquisitions, Escalating Expenses a Concern
by Zacks Equity Research
DaVita HealthCare Partners' (DVA) focus on acquisitions will boost the company's expansion. However, rising expenses remains headwind.
Hurricane Maria to Hurt Medtronic in Q2, FY18 View Intact
by Zacks Equity Research
Medtronic (MDT) expects normal manufacturing process in Puerto Rico to resume in full force in the coming weeks with considerable repairing done in the aftermath of Hurricane Maria.
Teleflex (TFX) Hits a 52-Week High on NeoTract Acquisition
by Zacks Equity Research
NeoTract acquisition is expected to generate mid-single digit constant currency revenue growth for the next several years and enhance Teleflex's (TFX) margins.
Integra's (IART) Revize/Revize-X Boosts Tissue Technology Arm
by Zacks Equity Research
Integra (IART) widens its tissue technology segment with the launch of Revize/Revize-X Collagen Matrix for plastic and reconstructive surgery.
Abbott (ABT) Hits a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
The market is upbeat about Abbott's (ABT) recent FDA approvals and buyouts.
QIAGEN's QFT-Plus Launch to Boost Molecular Diagnostics Arm
by Zacks Equity Research
QIAGEN (QGEN) strengthens its highest revenue grossing segment with the launch of QuantiFERON-TB Gold Plus in the United States.